Selected research
Industry Growth & Trends
Global Targeted Drugs for Multiple Sclerosis Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Targeted Drugs for Multiple Sclerosis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Targeted Drugs for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Targeted Drugs for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Targeted Drugs for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Targeted Drugs for Multiple Sclerosis market include NOVARTIS, Roche, Biogen, Sanofi, Janssen and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Targeted Drugs for Multiple Sclerosis market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Targeted Drugs for Multiple Sclerosis market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Targeted Drugs for Multiple Sclerosis market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Targeted Drugs for Multiple Sclerosis.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Targeted Drugs for Multiple Sclerosis market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Targeted Drugs for Multiple Sclerosis Market by Company
NOVARTIS
Roche
Biogen
Sanofi
Janssen
Bristol-Myers Squibb
Targeted Drugs for Multiple Sclerosis Segment by Type
Oral
Injection
Targeted Drugs for Multiple Sclerosis Segment by Application
Hospital
Clinic
Other
Targeted Drugs for Multiple Sclerosis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Drugs for Multiple Sclerosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeted Drugs for Multiple Sclerosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Drugs for Multiple Sclerosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Targeted Drugs for Multiple Sclerosis companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Hospital
- Clinic
- Other
Companies covered
- NOVARTIS
- Roche
- Biogen
- Sanofi
- Janssen
- Bristol-Myers Squibb
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Targeted Drugs for Multiple Sclerosis Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Targeted Drugs for Multiple Sclerosis Market Size by Region (2021-2032)
- 1.4.1 Global Targeted Drugs for Multiple Sclerosis Market Size by Region (2021-2026)
- 1.4.2 Global Targeted Drugs for Multiple Sclerosis Market Size by Region (2027-2032)
- 1.5 Key Regions Targeted Drugs for Multiple Sclerosis Market Size (2021-2032)
- 1.5.1 North America Targeted Drugs for Multiple Sclerosis Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Targeted Drugs for Multiple Sclerosis Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Targeted Drugs for Multiple Sclerosis Market Size Growth Rate (2021-2032)
- 1.5.4 South America Targeted Drugs for Multiple Sclerosis Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size Growth Rate (2021-2032)
2 Targeted Drugs for Multiple Sclerosis Market by Type
- 2.1 Type Introduction
- 2.1.1 Oral
- 2.1.2 Injection
- 2.2 Global Targeted Drugs for Multiple Sclerosis Market Size by Type
- 2.2.1 Global Targeted Drugs for Multiple Sclerosis Market Size Overview by Type (2021-2032)
- 2.2.2 Global Targeted Drugs for Multiple Sclerosis Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Targeted Drugs for Multiple Sclerosis Market Size Forecasted by Type (2027-2032)
- 2.3 Global Targeted Drugs for Multiple Sclerosis Market Size by Regions
- 2.3.1 North America Targeted Drugs for Multiple Sclerosis Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Targeted Drugs for Multiple Sclerosis Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Targeted Drugs for Multiple Sclerosis Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Targeted Drugs for Multiple Sclerosis Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Targeted Drugs for Multiple Sclerosis Market Size Breakdown by Type (2021-2026)
3 Targeted Drugs for Multiple Sclerosis Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Clinic
- 3.1.3 Other
- 3.2 Global Targeted Drugs for Multiple Sclerosis Market Size by Application
- 3.2.1 Global Targeted Drugs for Multiple Sclerosis Market Size Overview by Application (2021-2032)
- 3.2.2 Global Targeted Drugs for Multiple Sclerosis Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Targeted Drugs for Multiple Sclerosis Market Size Forecasted by Application (2027-2032)
- 3.3 Global Targeted Drugs for Multiple Sclerosis Market Size by Regions
- 3.3.1 North America Targeted Drugs for Multiple Sclerosis Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Targeted Drugs for Multiple Sclerosis Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Targeted Drugs for Multiple Sclerosis Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Targeted Drugs for Multiple Sclerosis Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Targeted Drugs for Multiple Sclerosis Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Targeted Drugs for Multiple Sclerosis Industry Trends
- 4.2 Targeted Drugs for Multiple Sclerosis Industry Drivers
- 4.3 Targeted Drugs for Multiple Sclerosis Industry Opportunities and Challenges
- 4.4 Targeted Drugs for Multiple Sclerosis Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Targeted Drugs for Multiple Sclerosis Revenue (2021-2026)
- 5.2 Global Targeted Drugs for Multiple Sclerosis Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Targeted Drugs for Multiple Sclerosis Key Company Headquarters & Area Served
- 5.4 Global Targeted Drugs for Multiple Sclerosis Company, Product Type & Application
- 5.5 Global Targeted Drugs for Multiple Sclerosis Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Targeted Drugs for Multiple Sclerosis Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Targeted Drugs for Multiple Sclerosis Players Market Share by Revenue in 2025
- 5.6.3 2025 Targeted Drugs for Multiple Sclerosis Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 NOVARTIS
- 6.1.1 NOVARTIS Company Information
- 6.1.2 NOVARTIS Business Overview
- 6.1.3 NOVARTIS Targeted Drugs for Multiple Sclerosis Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 NOVARTIS Targeted Drugs for Multiple Sclerosis Product Portfolio
- 6.1.5 NOVARTIS Recent Developments
- 6.2 Roche
- 6.2.1 Roche Company Information
- 6.2.2 Roche Business Overview
- 6.2.3 Roche Targeted Drugs for Multiple Sclerosis Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Roche Targeted Drugs for Multiple Sclerosis Product Portfolio
- 6.2.5 Roche Recent Developments
- 6.3 Biogen
- 6.3.1 Biogen Company Information
- 6.3.2 Biogen Business Overview
- 6.3.3 Biogen Targeted Drugs for Multiple Sclerosis Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Biogen Targeted Drugs for Multiple Sclerosis Product Portfolio
- 6.3.5 Biogen Recent Developments
- 6.4 Sanofi
- 6.4.1 Sanofi Company Information
- 6.4.2 Sanofi Business Overview
- 6.4.3 Sanofi Targeted Drugs for Multiple Sclerosis Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Sanofi Targeted Drugs for Multiple Sclerosis Product Portfolio
- 6.4.5 Sanofi Recent Developments
- 6.5 Janssen
- 6.5.1 Janssen Company Information
- 6.5.2 Janssen Business Overview
- 6.5.3 Janssen Targeted Drugs for Multiple Sclerosis Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Janssen Targeted Drugs for Multiple Sclerosis Product Portfolio
- 6.5.5 Janssen Recent Developments
- 6.6 Bristol-Myers Squibb
- 6.6.1 Bristol-Myers Squibb Company Information
- 6.6.2 Bristol-Myers Squibb Business Overview
- 6.6.3 Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Product Portfolio
- 6.6.5 Bristol-Myers Squibb Recent Developments
7 North America
- 7.1 North America Targeted Drugs for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Targeted Drugs for Multiple Sclerosis Market Size by Country (2021-2026)
- 7.3 North America Targeted Drugs for Multiple Sclerosis Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Targeted Drugs for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Targeted Drugs for Multiple Sclerosis Market Size by Country (2021-2026)
- 8.3 Europe Targeted Drugs for Multiple Sclerosis Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Targeted Drugs for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Targeted Drugs for Multiple Sclerosis Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Targeted Drugs for Multiple Sclerosis Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Targeted Drugs for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Targeted Drugs for Multiple Sclerosis Market Size by Country (2021-2026)
- 10.3 South America Targeted Drugs for Multiple Sclerosis Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst